Skip to main content
Premium Trial:

Request an Annual Quote

OliX Receives Government Grant to Develop Anti-scarring Drug

Premium

NEW YORK (GenomeWeb) — South Korea's OliX Pharmaceuticals announced that it has received an undisclosed amount of funding from the South Korean government to support the preclinical development of its siRNA-based anti-scarring drug candidate BMT 101.

The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis. Notably, RXi Pharmaceuticals' Phase II anti-scarring drug RXI-109 is also designed to inhibit this target.

"Based on successful preclinical results, we are looking forward to proceeding with international licensing-outs of BMT101 to multinational companies for the entry of mature markets like the US, Europe, and Japan," OliX CEO Sun-Woo Hong said in a statement.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.